Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective study

Ogata, Toru; Satake, Hironaga; Ogata, Masao; Hatachi, Yukimasa; Inoue, Kentaro; Hamada, Masanori; Yasui, Hisateru

doi:10.18632/oncotarget.26145

Cited by 54 publications

(48 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is consequently favorable to have more LYMs relative to neutrophils (i.e., a low NLR). Relationships between NLR and OS have been reported previously across both tumor‐types and checkpoint inhibitors . NLR provided nearly as good improvement as LYM in the AAD model (1.7 × 10 −4 vs. 1.0 × 10 −4 ; Table ) and could consequently have been exchanged to NLR with only minor worsening of the model fit.…”

Section: Discussionsupporting

confidence: 58%

“…Relationships between NLR and OS have been reported previously across both tumor-types and checkpoint inhibitors. 6,[35][36][37] NLR provided nearly as good improvement as LYM in the AAD model (1.7 × 10 −4 vs. 1.0 × 10 −4 ; Table S3) and could consequently have been exchanged to NLR with only minor worsening of the model fit. This was also confirmed in the KMMCVPC for NLR where AAD were well predicted by the models based on C2YE and C2YASOT data ( Figure S4).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Tumor Time‐Course Predicts Overall Survival in Non‐Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow‐Up Time

Netterberg

Bruno

Chen³

et al. 2020

CPT Pharmacom & Syst Pharma

View full text Add to dashboard Cite

The large heterogeneity in response to immune checkpoint inhibitors is driving the exploration of predictive biomarkers to identify patients who will respond to such treatment. We extended our previously suggested modeling framework of atezolizumab pharmacokinetics, IL18, and tumor size (TS) dynamics, to also include overall survival (OS). Baseline and model‐derived variables were explored as predictors of OS in 88 patients with non‐small cell lung cancer treated with atezolizumab. To investigate the impact of follow‐up length on the inclusion of predictors of OS, four different censoring strategies were applied. The time‐course of TS change was the most significant predictor in all scenarios, whereas IL18 was not significant. Identified predictors of OS were similar regardless of censoring strategy, although OS was underpredicted when patients were censored 5 months after last dose. The study demonstrated that the tumor‐time course‐OS relationship could be identified based on early phase I data.

show abstract

Section: Discussionsupporting

confidence: 58%

Section: Discussionmentioning

confidence: 99%

Tumor Time‐Course Predicts Overall Survival in Non‐Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow‐Up Time

Netterberg

Bruno

Chen³

et al. 2020

CPT Pharmacom & Syst Pharma

View full text Add to dashboard Cite

show abstract

“…Compared to patients with high NLRs, patients with low NLRs are likely to have the inflammatory reaction environment mediated by lymphocytes [30]. Ogata et al [33] and Bagley et al [34] reported that the NLR might predict the tumor response of nivolumab in gastric cancer and non-small cell lung cancer, respectively. Tada et al [35] reported that ramucirumab suppresses tumor infiltration of effector regulatory T-cells (eTreg) and decreases programmed cell death protein 1 (PD-1) expression by CD8+ T-cells, subsequently enhancing antitumor immunity.…”

Section: Discussionmentioning

confidence: 99%

Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer

et al. 2020

View full text Add to dashboard Cite

Background: Ramucirumab monotherapy as a second-line treatment for advanced gastric cancer (AGC) prolongs survival compared to the best supportive care. However, in clinical practice, ramucirumab monotherapy is sometimes used as third-or later-line treatment for AGC refractory to fluoropyrimidine and taxanes. This study evaluated the efficacy and safety of salvage-line ramucirumab monotherapy for treating AGC. Methods: The subjects of this retrospective study were advanced gastric or gastro-esophageal junction adenocarcinoma patients who received ramucirumab monotherapy after failure of 2 or more prior regimens containing fluoropyrimidine and taxanes but not ramucirumab. Results: From June 2015 to April 2017, 51 patients were enrolled. The median progression-free survival (PFS) and overall survival (OS) were 1.8 (95% confidence interval [CI] = 1.6-2.2) and 5.1 (95% CI = 4.0-6.8) months, respectively. The objective response and disease control rates were 2 and 17%, respectively. Grade 3 adverse events (AEs; e.g., anemia, fatigue, hypertension, proteinuria, intestinal bleeding) occurred in seven (13%) patients, but no grade 4 AEs and treatment-related deaths were observed. A neutrophil-lymphocyte ratio (NLR) of < 2.5 and previous gastrectomy were associated with better PFS. Conclusions: Salvage-line ramucirumab monotherapy has acceptable toxicity and comparable efficacy to second-line treatment; therefore, we consider physicians might choose this therapy as a salvage-line treatment option for AGC refractory to the standard therapies.

show abstract

“…An increasing number of studies has indicated that a high preoperative NLR is associated with poor patient outcome in various types of cancer, including pancreatic cancer, renal cancer, non-small cell lung cancer, gastric cancer, hepatocellular carcinoma, and various other solid tumors. [ 6 , 13 – 16 ] Using univariate and multivariate analysis, the present study investigated the relationship between multiple clinicopathological factors and the prognosis of DCC patients. It was ultimately confirmed that a high preoperative NLR (>2.933) is an independent risk factor for the overall survival rate of patients with DCC.…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of the neutrophil-to-lymphocyte ratio with distal cholangiocarcinoma patients

Kang²,

Wang³

et al. 2020

Medicine

View full text Add to dashboard Cite

Background: The present study aimed to investigate the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) in distal cholangiocarcinoma (DCC) following radical surgery. Methods: The clinicopathological data of 59 patients with DCC were retrospectively reviewed. Patients were treated by radical surgery and diagnosed by postoperative pathology at the Second Affiliated Hospital of Kunming Medical University (Yunnan, China), between July 2015 and December 2017. The optimal cut-off value for the NLR was determined by generating receiver operating characteristic (ROC) curves. Kaplan–Meier survival analysis and Cox proportional hazards models were used to determine the risk factors and independent risk factors influencing the prognosis of patients with DCC. Results: According to the ROC curve, the optimal cut-off value for the NLR was 2.933. The results of Kaplan–Meier survival analysis and the Cox proportional hazards model showed that carbohydrate antigen 125, NLR, perineural, vascular and fat invasion, regional lymph node metastasis, and the American Joint Committee on Cancer stage were risk factors for DCC; the only independent risk factor to affect the prognosis of DCC patients was the NLR. Conclusions: The preoperative NLR plays an important guiding role in evaluating the prognosis of patients with DCC, and an increase in the NLR is associated with poor patient prognosis.

show abstract

Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective study

Cited by 54 publications

References 23 publications

Tumor Time‐Course Predicts Overall Survival in Non‐Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow‐Up Time

Tumor Time‐Course Predicts Overall Survival in Non‐Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow‐Up Time

Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer

Prognostic significance of the neutrophil-to-lymphocyte ratio with distal cholangiocarcinoma patients

Contact Info

Product

Resources

About